Mathilde Cabart
Overview
Explore the profile of Mathilde Cabart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guegan J, Peyraud F, Dadone-Montaudie B, Teyssonneau D, Palmieri L, Clot E, et al.
Cell Rep Med
. 2024 Nov;
5(12):101831.
PMID: 39591972
Immune checkpoint inhibitors (ICIs) have advanced the treatment of non-small cell lung cancer (NSCLC). This study evaluates the predictive value of CD8 T cell exhaustion in patients with lung adenocarcinoma...
2.
Cabart M, Mourey L, Pasquier D, Schneider S, Lena H, Girard N, et al.
J Geriatr Oncol
. 2024 Jul;
15(7):101819.
PMID: 39068144
Introduction: In France, 40% of patients diagnosed with lung cancer are ≥70 years old, but these are under-represented in clinical trials. Using data from the French Epidemiological Strategy and Medical...
3.
Bessede A, Peyraud F, Besse B, Cousin S, Cabart M, Chomy F, et al.
Clin Cancer Res
. 2023 Dec;
30(4):779-785.
PMID: 38048058
Purpose: Mechanisms of primary resistance to inhibitors of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling axis in non-small cell lung cancer (NSCLC) are still poorly understood. While some...
4.
Mottet T, Hemar V, Enfedaque S, Mathoulin-Pelissier S, Charitansky H, Godbert Y, et al.
Acta Oncol
. 2023 Nov;
62(12):1905-1912.
PMID: 37948066
Introduction: Integrating telemedicine into cancer care remains a major challenge. There are little clinical evidence for teleconsultation efficacy and safety in daily oncology practice. This study as a pioneering experience,...
5.
Bessede A, Peyraud F, Moulec S, Cousin S, Cabart M, Chomy F, et al.
Clin Cancer Res
. 2023 Sep;
29(23):4883-4893.
PMID: 37756581
Purpose: Overexpression of the tryptophan-catabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1) has been reported in several tumor types, including non-small cell lung cancer (NSCLC), and has been shown to promote tumor-immune...
6.
Greillier L, Gauvrit M, Paillaud E, Girard N, Montegut C, Boulahssass R, et al.
Cancers (Basel)
. 2022 Feb;
14(3).
PMID: 35159036
Systematic molecular profiling and targeted therapy (TKI) have changed the face of Non-Small Cell Lung Cancer (NSCLC) treatment. However, there are no specific recommendations to address the prescription of TKI...
7.
Vanhersecke L, Brunet M, Guegan J, Rey C, Bougouin A, Cousin S, et al.
Nat Cancer
. 2022 Feb;
2(8):794-802.
PMID: 35118423
Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types....
8.
Bertolaso P, Brouste V, Cazeau A, de Clermont-Gallerande H, Bladou F, Cabart M, et al.
Clin Genitourin Cancer
. 2022 Feb;
20(3):297-297.e6.
PMID: 35101381
Introduction: Guidelines do not recommend FDG-PET CT for the staging of MIBC as a standard. The objectives of the study are to assess the accuracy of the FDG-PET CT for...
9.
Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong N, et al.
J Hematol Oncol
. 2021 Mar;
14(1):51.
PMID: 33781305
Despite survival improvements achieved over the last two decades, prostate cancer remains lethal at the metastatic castration-resistant stage (mCRPC) and new therapeutic approaches are needed. Germinal and/or somatic alterations of...
10.
Palussiere J, Catena V, Lagarde P, Cousin S, Cabart M, Buy X, et al.
Int J Hyperthermia
. 2019 Sep;
36(2):46-52.
PMID: 31537155
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer death; percutaneous thermal ablation (TA) has proven feasibility, good local control and good tolerance in stage I tumors for...